Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy
Copyright © 2024. Published by Elsevier Ltd..
BACKGROUND: Although carbon ion radiation therapy (CIRT) substantially improves the overall survival (OS) of patients with LR-NPC, approximately 40% of the patients may develop local recurrence. The purpose of study is to assess the value of tumor volume (TV) as a predictive tool to guide individualized CIRT.
METHODS: Consecutive patients with LR-NPC treated using CIRT at Shanghai Proton and Heavy Ion Center between April 2015 and May 2019 were included. TV before CIRT was delineated and calculated. The generalized additive Cox model was used to examine the relationship between TV and OS and local progression-free survival (LPFS). A cutoff value of tumor volume was identified to best discriminate patients with different 2-year OS rates, using receiver operating characteristic (ROC) analysis.
RESULTS: A total of 157 patients were enrolled. The median tumor volume was 22.49 (2.52-90.13) ml. In the univariable analyses, tumor volume was significantly associated with OS (p < 0.001) and LPFS (p = 0.01). The relationships with OS (p = 0.009) and LPFS (p = 0.020) remained significant in multivariable analyses. Using ROC analysis, a TV of 26.69 ml was identified to predict the 2-year OS rate. To facilitate potential clinical use, 25 ml was designated as the final cutoff value. The 2-year OS and LPFS rates were 88.6 % vs 62.3 %, and 54.7 % vs 35.5 %, for patients with a TV ≤ 25 ml and > 25 ml, respectively.
CONCLUSION: Tumor volume could predict the OS and LPFS of patients. We propose that tumor volume should be considered in the risk stratification and CIRT-based treatment for patients with LR-NPC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Oral oncology - 151(2024) vom: 09. Apr., Seite 106683 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Jiyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carbon ion radiotherapy |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2024.106683 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368772470 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368772470 | ||
| 003 | DE-627 | ||
| 005 | 20240408232421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2024.106683 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM368772470 | ||
| 035 | |a (NLM)38387259 | ||
| 035 | |a (PII)S1368-8375(24)00001-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Jiyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor volume instead of recurrent T category predicts clinical outcome of patients with locally recurrent nasopharyngeal carcinoma salvaged by carbon ion radiation therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Ltd. | ||
| 520 | |a BACKGROUND: Although carbon ion radiation therapy (CIRT) substantially improves the overall survival (OS) of patients with LR-NPC, approximately 40% of the patients may develop local recurrence. The purpose of study is to assess the value of tumor volume (TV) as a predictive tool to guide individualized CIRT | ||
| 520 | |a METHODS: Consecutive patients with LR-NPC treated using CIRT at Shanghai Proton and Heavy Ion Center between April 2015 and May 2019 were included. TV before CIRT was delineated and calculated. The generalized additive Cox model was used to examine the relationship between TV and OS and local progression-free survival (LPFS). A cutoff value of tumor volume was identified to best discriminate patients with different 2-year OS rates, using receiver operating characteristic (ROC) analysis | ||
| 520 | |a RESULTS: A total of 157 patients were enrolled. The median tumor volume was 22.49 (2.52-90.13) ml. In the univariable analyses, tumor volume was significantly associated with OS (p < 0.001) and LPFS (p = 0.01). The relationships with OS (p = 0.009) and LPFS (p = 0.020) remained significant in multivariable analyses. Using ROC analysis, a TV of 26.69 ml was identified to predict the 2-year OS rate. To facilitate potential clinical use, 25 ml was designated as the final cutoff value. The 2-year OS and LPFS rates were 88.6 % vs 62.3 %, and 54.7 % vs 35.5 %, for patients with a TV ≤ 25 ml and > 25 ml, respectively | ||
| 520 | |a CONCLUSION: Tumor volume could predict the OS and LPFS of patients. We propose that tumor volume should be considered in the risk stratification and CIRT-based treatment for patients with LR-NPC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Carbon ion radiotherapy | |
| 650 | 4 | |a Clinical outcome | |
| 650 | 4 | |a Predict | |
| 650 | 4 | |a Recurrent nasopharyngeal carcinoma | |
| 650 | 4 | |a Tumor volume | |
| 700 | 1 | |a Huang, Qingting |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Weixu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Xianxin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Haojiong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guangyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jiade Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 151(2024) vom: 09. Apr., Seite 106683 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2024 |g day:09 |g month:04 |g pages:106683 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2024.106683 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2024 |b 09 |c 04 |h 106683 | ||